Biognosys closes financing round and hires new CEO

Biognosys is a leader in targeted proteomics. The company was founded in 2008 and is based in Schlieren. Today the start-up announced the closing of an intermediate financing round with incumbent and new investors allowing Biognosys to further expand its business in Europe and the US.

In addition, Patrick Plewman was named Chief Executive Officer. Patrick holds a BA degree from the University of North Carolina at Chapel Hill and was awarded an MBA from Harvard Business School. Prior to joining Biognosys, Patrick was CEO of diaDexus where he led the company from concept to commercialization of the only FDA approved blood test to predict coronary heart disease and ischemic stroke. At diaDexus he raised over $100 million in multiple financing rounds. Previously while at SmithKline Beecham, he witnessed the transformation of pharmaceutical research powered by novel genomic technologies. “I believe novel proteomic technologies such as Biognosys’ Hyper Reaction Monitoring technology have similar transformative capabilities”, Patrick said.

“We are excited that Patrick joins our team. His expertise in molecular diagnostics and raising capital will be invaluable to the continued success of Biognosys”, said Oliver Rinner, CSO of Biognosys.


Biognosys’ breakthrough mass spectrometric technology allows the simultaneous measurement of thousands of proteins in a single sample. The information is then stored in a digital map, which acts as a tool to monitor health, detect the onset of diseases, and discover biomarkers. Customers are Novartis V&D, GSK, Kenta, Delenex and Syngenta among others.